State Street Corporation (SLS) discloses 7% ownership of SELLAS Life Sciences common stock
Rhea-AI Filing Summary
State Street Corporation and certain investment adviser subsidiaries reported passive ownership of common stock of SELLAS Life Sciences Group Inc on a Schedule 13G. As of 06/30/2026, they beneficially owned 12,996,558 shares of common stock, representing 7% of the outstanding class. The group held 12,677,559 shares with shared voting power and 12,996,558 shares with shared dispositive power, with no sole voting or dispositive authority reported. Subsidiaries involved include SSGA Funds Management, Inc. and several State Street Global Advisors entities.
Positive
- None.
Negative
- None.
Key Figures
Beneficial ownership: 12,996,558 shares
Percent of class: 7%
Shared voting power: 12,677,559 shares
+3 more
6 metrics
Beneficial ownership
12,996,558 shares
Shares of SELLAS Life Sciences Group Inc common stock beneficially owned by State Street entities
Percent of class
7%
Percentage of SELLAS Life Sciences Group Inc common stock class beneficially owned
Shared voting power
12,677,559 shares
Shares over which State Street reports shared power to vote or direct the vote
Shared dispositive power
12,996,558 shares
Shares over which State Street reports shared power to dispose or direct disposition
Sole voting power
0
Shares over which State Street reports sole power to vote
Sole dispositive power
0
Shares over which State Street reports sole power to dispose
Key Terms
beneficially owned, shared voting power, shared dispositive power, parent holding company, +2 more
6 terms
beneficially owned financial
"Amount beneficially owned: 12996558.00"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
parent holding company financial
"If a parent holding company has filed this schedule"
investment company financial
"shareholders of an investment company registered under the Investment Company Act"
Schedule 13G regulatory
"If a parent holding company has filed this schedule"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What stake in SELLAS Life Sciences Group Inc (SLS) does State Street report on this Schedule 13G?
State Street and affiliates report beneficial ownership of 12,996,558 SELLAS Life Sciences Group Inc common shares, representing 7% of the class as of 06/30/2026, based on their Schedule 13G filing.
How much voting power does State Street have in SELLAS Life Sciences Group Inc (SLS)?
State Street reports shared voting power over 12,677,559 shares of SELLAS Life Sciences Group Inc common stock and no sole voting power, indicating votes are exercised jointly for those shares.
What dispositive power does State Street hold over SLS common stock?
State Street reports shared dispositive power over 12,996,558 shares of SELLAS Life Sciences Group Inc common stock and no sole dispositive power, meaning sell or transfer decisions are made on a shared basis.
Which State Street entities are involved in the SLS 13G filing?
The filing lists SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd., each classified as an investment adviser (IA).
Who signed the Schedule 13G for SELLAS Life Sciences Group Inc (SLS)?
The Schedule 13G was signed by Elizabeth Schaefer, Senior Vice President and Chief Accounting Officer of State Street Corporation, dated 08/07/2026, certifying the ownership information disclosed.